aminoglutethimide has been researched along with Local Neoplasm Recurrence in 27 studies
Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether the addition of aminoglutethimide to tamoxifen is able to improve the outcome in postmenopausal patients with hormone receptor-positive, early-stage breast cancer." | 9.10 | Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kubista, E; Kwasny, W; Menzel, C; Mlineritsch, B; Samonigg, H; Schmid, M; Seifert, M; Steger, G; Steindorfer, P; Stierer, M; Taucher, S; Tausch, C; Wette, V, 2003) |
| "Three hundred eighty postmenopausal breast cancer patients receiving adjuvant tamoxifen treatment for 3 years were randomized to either continue tamoxifen for 2 more years or to switch to low-dose aminoglutethimide (250 mg daily) for 2 years." | 9.09 | Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. ( Amoroso, D; Boccardo, F; Caroti, C; Cruciani, G; Farris, A; Mesiti, M; Mustacchi, G; Romeo, D; Rubagotti, A; Schieppati, G; Villa, E, 2001) |
| "In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared." | 9.06 | Megestrol acetate versus aminoglutethimide for metastatic breast cancer. ( Gundersen, S; Klepp, R; Kvinnsland, S; Lund, E; Lundgren, S; Lønning, PE, 1989) |
| "About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs." | 7.67 | Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1984) |
| "This study was performed to determine the toxicity and effectiveness of megestrol acetate used with aminoglutethimide-hydrocortisone in the treatment of patients with metastatic breast cancer." | 7.67 | Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide. ( Gale, KE; Hahn, RG; Horton, J; Keller, AM; Knuiman, M; Rosenbluth, RJ; Tormey, DC; Vogel, H, 1987) |
| "In a phase II study, 38 evaluable patients with advanced progressive breast cancer were treated with 4 X 250 mg of aminoglutethimide per day without hydrocortisone supplementation." | 7.67 | Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. ( Faber, P; Höffken, K; Kempf, H; Kley, HK; Miller, AA; Miller, B; Schmidt, CG, 1986) |
| "Sixty-five patients with advanced breast cancer, progressive despite prior endocrine therapy in all cases and prior chemotherapy in most cases, were treated with aminoglutethimide, 250 mg four times a day." | 7.66 | Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. ( Coates, AS; Fox, RM; Kaye, SB; Tattersall, MH; Woods, RL, 1982) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 6.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "To determine whether the addition of aminoglutethimide to tamoxifen is able to improve the outcome in postmenopausal patients with hormone receptor-positive, early-stage breast cancer." | 5.10 | Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kubista, E; Kwasny, W; Menzel, C; Mlineritsch, B; Samonigg, H; Schmid, M; Seifert, M; Steger, G; Steindorfer, P; Stierer, M; Taucher, S; Tausch, C; Wette, V, 2003) |
| "Three hundred eighty postmenopausal breast cancer patients receiving adjuvant tamoxifen treatment for 3 years were randomized to either continue tamoxifen for 2 more years or to switch to low-dose aminoglutethimide (250 mg daily) for 2 years." | 5.09 | Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. ( Amoroso, D; Boccardo, F; Caroti, C; Cruciani, G; Farris, A; Mesiti, M; Mustacchi, G; Romeo, D; Rubagotti, A; Schieppati, G; Villa, E, 2001) |
| "In order to evaluate the effectiveness of second and third line hormone therapy for postmenopausal (spontaneous or surgical) women with metastatic tamoxifen-resistant breast cancer, 293 women aged 36 to 91 (mean 63." | 5.07 | [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients]. ( Ayme, Y; Carton, M; Daban, A; Delozier, T; Fargeot, P; Ferri, L; Fumoleau, P; Garcia-Giralt, E; Gorins, A; Omodei Zorini, C, 1994) |
| "In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared." | 5.06 | Megestrol acetate versus aminoglutethimide for metastatic breast cancer. ( Gundersen, S; Klepp, R; Kvinnsland, S; Lund, E; Lundgren, S; Lønning, PE, 1989) |
| "About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs." | 3.67 | Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1984) |
| "This study was performed to determine the toxicity and effectiveness of megestrol acetate used with aminoglutethimide-hydrocortisone in the treatment of patients with metastatic breast cancer." | 3.67 | Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide. ( Gale, KE; Hahn, RG; Horton, J; Keller, AM; Knuiman, M; Rosenbluth, RJ; Tormey, DC; Vogel, H, 1987) |
| "In a phase II study, 38 evaluable patients with advanced progressive breast cancer were treated with 4 X 250 mg of aminoglutethimide per day without hydrocortisone supplementation." | 3.67 | Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. ( Faber, P; Höffken, K; Kempf, H; Kley, HK; Miller, AA; Miller, B; Schmidt, CG, 1986) |
| "Sixty-five patients with advanced breast cancer, progressive despite prior endocrine therapy in all cases and prior chemotherapy in most cases, were treated with aminoglutethimide, 250 mg four times a day." | 3.66 | Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. ( Coates, AS; Fox, RM; Kaye, SB; Tattersall, MH; Woods, RL, 1982) |
| "The term "hormone-refractory" prostate cancer has evolved to include patients with a spectrum of diseases." | 2.39 | Hormone-refractory (D3) prostate cancer: refining the concept. ( Kelly, WK; Scher, HI; Steineck, G, 1995) |
| " There is a tendency towards an increased response-rate with increased dosage of progestin, in both endometrial and breast carcinoma, while the route of administration appears to be of minor importance." | 2.37 | Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations. ( Kauppila, A, 1984) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 2.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "Tamoxifen was tried in three patients after relapse following adrenalectomy; all three patients responded with a mean duration of 9 months." | 1.27 | Metastatic breast cancer in males. Assessment of endocrine therapy. ( Dao, TL; Nemoto, T; Patel, JK, 1984) |
| "14 males with disseminated cancer of breast received a total of 35 endocrine trials, mainly in the form of hormonal supplementation." | 1.27 | Hormonal treatment of disseminated male breast cancer. ( Di Lauro, L; Lazzaro, B; Lopez, M; Papaldo, P, 1985) |
| "42 patients with metastatic breast carcinoma were treated with aminoglutethimide, which inhibits adrenal steroid hormone synthesis." | 1.26 | Aminoglutethimide in treatment of metastatic breast carcinoma. ( Fahmy, DR; Fitzharris, BM; Ford, HT; Gazet, JC; McKinna, JA; Nash, AG; Neville, AM; Powles, TJ; Smith, IE, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (77.78) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 2 (7.41) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schmid, M | 1 |
| Jakesz, R | 1 |
| Samonigg, H | 1 |
| Kubista, E | 1 |
| Gnant, M | 1 |
| Menzel, C | 1 |
| Seifert, M | 1 |
| Haider, K | 1 |
| Taucher, S | 1 |
| Mlineritsch, B | 1 |
| Steindorfer, P | 1 |
| Kwasny, W | 1 |
| Stierer, M | 1 |
| Tausch, C | 1 |
| Fridrik, M | 1 |
| Wette, V | 1 |
| Steger, G | 1 |
| Hausmaninger, H | 1 |
| Kaye, SB | 1 |
| Woods, RL | 1 |
| Fox, RM | 1 |
| Coates, AS | 1 |
| Tattersall, MH | 1 |
| Patel, JK | 1 |
| Nemoto, T | 1 |
| Dao, TL | 1 |
| Dowsett, M | 2 |
| Harris, AL | 3 |
| Smith, IE | 2 |
| Jeffcoate, SL | 1 |
| Kauppila, A | 1 |
| Taylor, RE | 1 |
| Powles, TJ | 2 |
| Humphreys, J | 1 |
| Bettelheim, R | 1 |
| Casey, AJ | 1 |
| Neville, AM | 2 |
| Coombes, RC | 1 |
| Wells, SA | 2 |
| Worgul, TJ | 1 |
| Samojlik, E | 2 |
| Boucher, AE | 1 |
| Lipton, A | 2 |
| Harvey, H | 2 |
| White, D | 1 |
| Smart, E | 1 |
| Cox, C | 1 |
| Santen, RJ | 2 |
| Ingle, JN | 1 |
| Green, SJ | 1 |
| Ahmann, DL | 1 |
| Edmonson, JH | 1 |
| Nichols, WC | 1 |
| Frytak, S | 1 |
| Rubin, J | 1 |
| Costanza, ME | 1 |
| Scher, HI | 2 |
| Steineck, G | 1 |
| Kelly, WK | 2 |
| Garcia-Giralt, E | 1 |
| Omodei Zorini, C | 1 |
| Ferri, L | 1 |
| Ayme, Y | 1 |
| Carton, M | 1 |
| Daban, A | 1 |
| Delozier, T | 1 |
| Fargeot, P | 1 |
| Fumoleau, P | 1 |
| Gorins, A | 1 |
| Zhang, ZF | 1 |
| Nanus, D | 1 |
| Boccardo, F | 1 |
| Rubagotti, A | 1 |
| Amoroso, D | 1 |
| Mesiti, M | 1 |
| Romeo, D | 1 |
| Caroti, C | 1 |
| Farris, A | 1 |
| Cruciani, G | 1 |
| Villa, E | 1 |
| Schieppati, G | 1 |
| Mustacchi, G | 1 |
| Fitzharris, BM | 1 |
| McKinna, JA | 1 |
| Fahmy, DR | 1 |
| Nash, AG | 1 |
| Gazet, JC | 1 |
| Ford, HT | 1 |
| Ruby, EB | 1 |
| Kendall, J | 1 |
| Seymour, L | 1 |
| Bezwoda, WR | 1 |
| Meyer, K | 1 |
| Nicholson, S | 2 |
| Sainsbury, JR | 2 |
| Halcrow, P | 2 |
| Chambers, P | 2 |
| Farndon, JR | 2 |
| Lundgren, S | 1 |
| Gundersen, S | 1 |
| Klepp, R | 1 |
| Lønning, PE | 1 |
| Lund, E | 1 |
| Kvinnsland, S | 1 |
| Labrie, F | 1 |
| Dupont, A | 1 |
| Bélanger, A | 1 |
| Cusan, L | 1 |
| Brochu, M | 1 |
| Turina, E | 1 |
| Pinault, S | 1 |
| Lacourciere, Y | 1 |
| Emond, J | 1 |
| Andersen, J | 1 |
| Poulsen, HS | 1 |
| Lopez, M | 1 |
| Di Lauro, L | 1 |
| Lazzaro, B | 1 |
| Papaldo, P | 1 |
| Grem, JL | 1 |
| Falkson, G | 1 |
| Love, RR | 1 |
| Tormey, DC | 2 |
| Angus, B | 1 |
| Horton, J | 1 |
| Knuiman, M | 1 |
| Keller, AM | 1 |
| Vogel, H | 1 |
| Gale, KE | 1 |
| Hahn, RG | 1 |
| Rosenbluth, RJ | 1 |
| Höffken, K | 1 |
| Kempf, H | 1 |
| Miller, AA | 1 |
| Miller, B | 1 |
| Schmidt, CG | 1 |
| Faber, P | 1 |
| Kley, HK | 1 |
| Paterson, AH | 1 |
| Howell, A | 1 |
| Ribeiro, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal, Hormone Receptor-positive Patients[NCT00309491] | Phase 3 | 2,021 participants (Actual) | Interventional | 1990-12-31 | Completed | ||
| A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormon[NCT02730923] | Phase 1/Phase 2 | 72 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for aminoglutethimide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bromocriptine; | 1984 |
Hormone-refractory (D3) prostate cancer: refining the concept.
Topics: Aminoglutethimide; Clinical Trials as Topic; Cortisone; Dexamethasone; Drug Therapy, Combination; Hu | 1995 |
Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer.
Topics: Aminoglutethimide; Androgen Antagonists; Clinical Trials as Topic; Flutamide; Humans; Male; Neoplasm | 1996 |
Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Topics: Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehy | 1977 |
6 trials available for aminoglutethimide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
Topics: Aged; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Proto | 2003 |
Comparison of surgical adrenalectomy to medical adrenalectomy in patients with metastatic carcinoma of the breast.
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Hydroc | 1982 |
Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combinatio | 1982 |
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Drug Resistance; Female; Humans | 1994 |
Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study.
Topics: Aged; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Resista | 2001 |
Megestrol acetate versus aminoglutethimide for metastatic breast cancer.
Topics: Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; Megest | 1989 |
17 other studies available for aminoglutethimide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Humans; Middle Aged; Nause | 1982 |
Metastatic breast cancer in males. Assessment of endocrine therapy.
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Humans; Male; Middle Ag | 1984 |
Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
Topics: Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrone; Fe | 1984 |
Effects of endocrine therapy on steroid-receptor content of breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Estrogen Antagonists; Estrogens, Conju | 1982 |
The medical management of breast cancer.
Topics: Adjuvants, Pharmaceutic; Adult; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Castrati | 1982 |
Aminoglutethimide in treatment of metastatic breast carcinoma.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neopl | 1978 |
Response to second-line hormone treatment for advanced breast cancer. Predictive value of ploidy determination.
Topics: Aminoglutethimide; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dip | 1990 |
Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Drug Administration Schedule; ErbB Receptors; Fema | 1989 |
Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flutam | 1989 |
Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diethylst | 1989 |
Hormonal treatment of disseminated male breast cancer.
Topics: Adult; Aminoglutethimide; Androgen Antagonists; Antineoplastic Agents; Breast Neoplasms; Castration; | 1985 |
A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 1988 |
Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; ErbB Receptors; Female; Humans; Hydroc | 1988 |
Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; B | 1987 |
Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Drug Evaluation; Female; Hormones; | 1986 |
Chemotherapy and hormone therapy of metastatic breast cancer.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali | 1985 |
Management of advanced carcinoma of the breast.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali | 1985 |